TNX-1900 is under clinical development by Tonix Pharmaceuticals Holding and currently in Phase II for Binge Eating Disorder. According to GlobalData, Phase II drugs for Binge Eating Disorder have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TNX-1900’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxytocin (TI-001) is under development for the treatment of chronic migraine, binge eating disorder, social anxiety disorder (SAD), obesity in adults and pediatrics. The drug candidate is an intranasal oxytocin formulation. It acts by targeting oxytocin receptor and CGRP (Calcitonin Gene Related Peptide) . It was also under development for the treatment of trigeminal neuralgia, chronic daily headache (CDH), craniofacial pain, mild traumatic brain injury, binge eating disorder, insulin resistance and obesity.
For a complete picture of TNX-1900’s drug-specific PTSR and LoA scores, buy the report here.